S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Why Your IRA Could Crash on January 16th? (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Why Your IRA Could Crash on January 16th? (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Why Your IRA Could Crash on January 16th? (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Why Your IRA Could Crash on January 16th? (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
NASDAQ:BNTX

BioNTech - BNTX Stock Forecast, Price & News

$162.63
+1.01 (+0.62%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$159.51
$165.97
50-Day Range
$118.43
$169.74
52-Week Range
$117.08
$312.96
Volume
600,075 shs
Average Volume
1.35 million shs
Market Capitalization
$39.47 billion
P/E Ratio
3.67
Dividend Yield
N/A
Price Target
$217.15

BioNTech MarketRank™ Forecast

Analyst Rating
Hold
2.46 Rating Score
Upside/​Downside
26.8% Upside
$206.17 Price Target
Short Interest
Healthy
0.77% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.21mentions of BioNTech in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-50.45%
From $35.38 to $17.53 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

776th out of 1,027 stocks

Biological Products, Except Diagnostic Industry

126th out of 171 stocks

BNTX stock logo

About BioNTech (NASDAQ:BNTX) Stock

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

BNTX Stock News Headlines

Brokerages Set BioNTech SE (NASDAQ:BNTX) Target Price at $217.15
BioNTech (BNTX) Inks Research Deal With Ryvu Therapeutics
Here are the Reasons to Invest in BioNTech SE (BNTX)
BioNTech Third Quarter 2022 Earnings: Beats Expectations
BioNTech SE (BNTX) Q3 2022 Earnings Call Transcript
BioNTech Shares Up On Hope For Combined Flu, Covid Shot
Is BioNTech a Good Long-Term Buy?
BioNTech SE stock performance and analyst projections
See More Headlines
Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

BNTX Company Calendar

Last Earnings
11/07/2022
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/29/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BNTX
Employees
3,082
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$206.17
High Stock Price Forecast
$312.00
Low Stock Price Forecast
$148.00
Forecasted Upside/Downside
+33.5%
Consensus Rating
Hold
Rating Score (0-4)
2.46
Research Coverage
12 Analysts

Profitability

Net Income
$12.18 billion
Pretax Margin
78.69%

Debt

Sales & Book Value

Annual Sales
$22.45 billion
Cash Flow
$49.28 per share
Book Value
$58.02 per share

Miscellaneous

Free Float
196,089,000
Market Cap
$39.47 billion
Optionable
Not Optionable
Beta
0.16

Social Links


Key Executives

  • Prof. Ugur Sahin M.D. (Age 57)
    Co-Founder, CEO & Chair of the Management Board
    Comp: $680.28k
  • Dr. Ozlem Tureci M.D. (Age 55)
    Co-Founder, Chief Medical Officer & Member of Management Board
    Comp: $674.26k
  • Prof. Christoph Hubert Huber M.D. (Age 78)
    Ph.D., Co-Founder & Member of Supervisory Board
    Comp: $59.11k
  • Mr. Jens H. Holstein (Age 59)
    CFO & Member of Management Board
    Comp: $815.53k
  • Dr. Sierk Poetting Ph.D. (Age 49)
    MD, COO & Member of Management Board
    Comp: $714.34k
  • Mr. Ryan Richardson (Age 43)
    Chief Strategy Officer, MD & Member of Management Board
    Comp: $617.16k
  • Mr. Sean Marett (Age 57)
    Chief Bus. Officer, Chief Commercial Officer & Member of Management Board
    Comp: $771.45k
  • Sylke Maas Ph.D.
    VP of Investor Relations and Bus. Strategy
  • Dr. James Timothy Patrick Ryan Ph.D.
    Sr. VP & Gen. Counsel
  • Michael Boehler
    MD & Head of Global External Communications













BNTX Stock - Frequently Asked Questions

Should I buy or sell BioNTech stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BNTX shares.
View BNTX analyst ratings
or view top-rated stocks.

What is BioNTech's stock price forecast for 2023?

12 brokers have issued twelve-month target prices for BioNTech's stock. Their BNTX share price forecasts range from $148.00 to $312.00. On average, they anticipate the company's stock price to reach $206.17 in the next year. This suggests a possible upside of 26.8% from the stock's current price.
View analysts price targets for BNTX
or view top-rated stocks among Wall Street analysts.

How have BNTX shares performed in 2022?

BioNTech's stock was trading at $257.80 on January 1st, 2022. Since then, BNTX stock has decreased by 36.9% and is now trading at $162.63.
View the best growth stocks for 2022 here
.

Are investors shorting BioNTech?

BioNTech saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 1,880,000 shares, a decline of 12.1% from the October 31st total of 2,140,000 shares. Based on an average daily trading volume, of 861,900 shares, the days-to-cover ratio is currently 2.2 days.
View BioNTech's Short Interest
.

When is BioNTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our BNTX earnings forecast
.

How were BioNTech's earnings last quarter?

BioNTech SE (NASDAQ:BNTX) issued its quarterly earnings results on Monday, November, 7th. The company reported $7.04 EPS for the quarter, beating analysts' consensus estimates of $3.66 by $3.38. The firm had revenue of $3.46 billion for the quarter, compared to the consensus estimate of $1.90 billion. BioNTech had a net margin of 55.72% and a trailing twelve-month return on equity of 66.45%. The firm's quarterly revenue was down 43.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $14.56 EPS.

How often does BioNTech pay dividends? What is the dividend yield for BioNTech?

BioNTech declared a -- dividend on Thursday, April 28th. Shareholders of record on Friday, June 3rd will be paid a dividend of $1.5342 per share on Friday, June 17th. This represents a dividend yield of 1.1%. The ex-dividend date is Thursday, June 2nd.
Read our dividend analysis for BNTX
.

What is Ugur Sahin's approval rating as BioNTech's CEO?

33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend.

What other stocks do shareholders of BioNTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD).

When did BioNTech IPO?

(BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

What is BioNTech's stock symbol?

BioNTech trades on the NASDAQ under the ticker symbol "BNTX."

Who are BioNTech's major shareholders?

BioNTech's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (2.99%), Temasek Holdings Private Ltd (1.80%), Primecap Management Co. CA (1.73%), Flossbach Von Storch AG (1.39%), Artisan Partners Limited Partnership (0.92%) and BlackRock Inc. (0.62%).

How do I buy shares of BioNTech?

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioNTech's stock price today?

One share of BNTX stock can currently be purchased for approximately $162.63.

How much money does BioNTech make?

BioNTech (NASDAQ:BNTX) has a market capitalization of $39.47 billion and generates $22.45 billion in revenue each year. The company earns $12.18 billion in net income (profit) each year or $44.26 on an earnings per share basis.

How many employees does BioNTech have?

The company employs 3,082 workers across the globe.

Does BioNTech have any subsidiaries?
The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.
Read More
How can I contact BioNTech?

BioNTech's mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The official website for the company is www.biontech.de. The company can be reached via phone at 49-61-31908-40, via email at investors@biontech.de, or via fax at 49-6131-908-4390.

This page (NASDAQ:BNTX) was last updated on 12/8/2022 by MarketBeat.com Staff